Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.
The company said that it was stopping access to the drug for new patients immediately, while those already taking it would be able to continue on it via a free drug programme, after consultation with their doctors – a move that has garnered praise from across the biopharma industry.
